Inicio
Este sitio está destinado a profesionales de la salud.

Paradigmas en evolución en el cáncer de pulmón: Módulo 3 – Evidencia clínica de los anticuerpos biespecíficos

Compartir

Descripción

Esta actividad cuenta con el apoyo de una subvención independiente para educación médica de la Alianza BioNTech-BMS. Este programa de formación en línea ha sido diseñado para profesionales sanitarios de todo el mundo.

Acompañe al Dr. Edward Garon mientras explora el papel cada vez más relevante de la medicina de precisión en el cáncer de pulmón no microcítico (CPNPC). Este módulo de microaprendizaje dirigido por expertos analiza los biomarcadores que orientan la selección del tratamiento, desde las alteraciones genómicas accionables hasta biomarcadores de inmunoterapia como la expresión de PD-L1 y la carga mutacional tumoral, destacando además biomarcadores moleculares emergentes que podrían perfeccionar aún más las estrategias de tratamiento personalizado.

¿Prefiere leer en su lugar? Consulte nuestro Resumen Clínico Clave aquí.

Aspectos destacados de la sesión

  • Revise la evolución de la medicina de precisión en el CPNPC, desde un enfoque terapéutico basado en la histología hasta la toma de decisiones guiada por biomarcadores.
  • Comprenda la utilidad clínica de los biomarcadores consolidados, incluidas las alteraciones genómicas accionables, la expresión de PD-L1 y la carga mutacional tumoral, para seleccionar las terapias más adecuadas.
  • Explore la evidencia que respalda los biomarcadores de inmunoterapia y cómo influyen en la selección de pacientes y en los resultados del tratamiento.
  • Analice los biomarcadores moleculares emergentes, incluidas las mutaciones en STK11 y KEAP1, y su posible papel en el perfeccionamiento de las futuras estrategias terapéuticas.

Público objetivo

Esta actividad está dirigida a oncólogos médicos, neumólogos, enfermeros especializados (nurse practitioners), asistentes médicos (physician associates), farmacéuticos, personal de enfermería y otros profesionales sanitarios implicados en la atención de pacientes con cáncer de pulmón, incluido el cáncer de pulmón no microcítico (CPNPC) y el cáncer de pulmón microcítico (CPM).

Profesorado

El Dr. Edward Garon es Director del Programa de Oncología Torácica del Jonsson Comprehensive Cancer Center de la UCLA y Profesor Asociado de la UCLA. Reconocido especialista en oncología torácica, sus intereses clínicos y de investigación se centran en el cáncer de pulmón, el desarrollo de biomarcadores y la innovación en ensayos clínicos. El Dr. Garon ha dirigido numerosos ensayos clínicos nacionales e internacionales de fases I–III, incluidos estudios que contribuyeron a la aprobación de múltiples terapias oncológicas y de un diagnóstico complementario.

Declaraciones de intereses

De acuerdo con las directrices de EBAC®, todos los ponentes y moderadores que participan en este programa han declarado cualquier posible conflicto de interés que pudiera influir en sus presentaciones. El Comité Organizador/Director del Curso es responsable de garantizar que todos los posibles conflictos de interés relevantes para el evento se comuniquen a los participantes antes del inicio de las actividades de formación continuada.

El Dr. Edward Garon, miembro del profesorado de esta actividad, ha declarado las siguientes relaciones financieras mantenidas durante los últimos 36 meses con las siguientes empresas no elegibles:

Consultor y/o asesor de: AbbVie, AstraZeneca, Arrivent, Bayer, Bicycle, Black Diamond Therapeutics, BridgeBio, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Gilead, Hexagon, I-Mab, IO Biotech, iTeos, Merck, Nuvalent, Oxford Bio, Pfizer, Regeneron, Samsung, Sanofi, Servier, Strata, Synthekine, Transcode y Verastem.

Subvenciones/Apoyo a la investigación (institucional) de: ABL-Bio, Arrivent, AstraZeneca, Bayer, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Iovance Biotherapeutics, Merck, Novartis, Prelude, Regeneron, Synthekine y TILT Biotherapeutics.

Propiedad intelectual: Motif Neoepitopes for Cancer Immunotherapy.

El personal de MedAll, así como los planificadores y revisores, no tienen relaciones financieras relevantes con empresas no elegibles que deban declarar.

Información sobre la acreditación EBAC® CME

Esta actividad ha sido planificada e implementada de acuerdo con los requisitos y políticas de acreditación del European Board for Accreditation of Continuing Education for Health Professionals (EBAC).

MedAll es un proveedor acreditado por EBAC desde 2025. El European Board for Accreditation of Continuing Education for Health Professionals (EBAC) acredita programas de formación médica continuada (CE) dirigidos a la comunidad médica internacional.

Este programa está acreditado por el European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) por 15 minutos de formación efectiva.

En cumplimiento de las directrices de EBAC, todos los ponentes y presidentes de sesión que participan en este programa han declarado o indicado cualquier posible conflicto de interés que pudiera introducir sesgos en sus presentaciones. El Comité Organizador/Director del Curso es responsable de garantizar que todos los posibles conflictos de interés relevantes para el evento sean comunicados a los participantes antes del inicio de las actividades de formación continuada.

EBAC® mantiene acuerdos de reconocimiento mutuo de equivalencia sustancial con el Accreditation Council for Continuing Medical Education (ACCME) de los Estados Unidos y con el Royal College of Physicians and Surgeons of Canada.

Gracias a un acuerdo entre el European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) y la American Medical Association (AMA), los médicos pueden convertir los créditos EBAC® de CME externos en AMA PRA Category 1 Credits™. La información sobre el proceso de conversión de créditos EBAC® a créditos AMA está disponible en el sitio web de la AMA. Otros profesionales sanitarios pueden obtener de la AMA un certificado de participación en una actividad susceptible de conversión a AMA PRA Category 1 Credit™.

El Accreditation Council for Continuing Medical Education (ACCME) y el Royal College of Physicians and Surgeons of Canada mantienen un acuerdo de equivalencia sustancial de sus sistemas de acreditación con EBAC.

EBAC® es miembro de la International Academy for CPD Accreditation (IACPDA) y miembro asociado de la International Association of Medical Regulatory Authorities (IAMRA).

Cómo obtener su crédito EBAC® CME

Para obtener su crédito CME y descargar su certificado, participe en la actividad y complete la evaluación al finalizar. Una vez completada la evaluación, recibirá un enlace para acceder a su certificado.

Coste de participación

La participación en este programa es gratuita.

Esta actividad de formación continuada estará disponible desde el 22 de julio de 2026 hasta el 14 de julio de 2027.

Tiempo estimado para completar esta actividad: 15 minutos.

Comunidades similares

Ver todo

Eventos y vídeos bajo demanda similares

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

I'm Edward Garin, uh, and I will be presenting now on precision Patient selection. Um, this is, of course, going to focus on patients with non-small cell lung cancer. Before we begin, these are our disclosures. Please find here the detailed accreditation information. And finally, please take note of this information. We will begin with a polling question. Uh, this is a 60-year-old patient with non-small cell lung cancer, um, who has a tumor with PDL1 expression of 0%. Uh, comprehensive genomic profiling reveals a very high non-synonymous tumor mutation burden. Um, we're discussing the rationale for utilizing immunotherapy despite the negative PDL-1 status. And Um, based on the foundational discovery cohorts evaluating the genomic landscape of non-small cell lung cancer, uh, from Nya Rizvi and colleagues, uh, how does a non-synonymous, uh, tumor mutation burden correlate with clinical outcomes for patients treated with a PD1 pathway blockade? And the choices here are A, uh, high mutational burden is strongly associated with improved progression-free survival. Uh, B, high mutational burden only improves overall survival if the patient also has an EGFR mutation. C, high mutational burden is associated with worse PFS due to hyperprogression. Or D, high mutational burden has no correlation with progression-free survival. It only predicts toxicity. So, uh, standard of care for many years, uh, going into the mid 2000s was, uh, at least in the United States, a combination of carboplatin and paclitaxel, um, in this, uh, figure here, this is the pink bar, uh, noted as PC. Um, there was uh, uh, what at the time was considered to be a major advance, uh, the addition of bevacizumab. Bevacizumab is a monoclonal antibody targeting VEGF. And, um, you can see in the dash blue line, the combination of bevacizumab, paclitaxel, and carboplatin. Uh, showed an improvement in overall survival. You can see the outcome data here with respect to response rate, um, overall survival, as well as progression-free survival, all favoring, uh, the bevacizumab, uh, arm. The, um, the curves eventually do appear to come together at the end. Um, but at least for the field psychologically, this was also a big advance is, in, in that it was the first time. Um, that we had really shown survival over a year, um, at that point in patients with, uh, stage 4 non-small cell lung cancer. Um, although it's not necessarily exactly what we think of when we think of, uh, precision medicine. Um, I think it's important to note that, uh, one thing that did shape the field is really two medicines, uh, that really separated the management of, uh, squamous cell disease from non-squamous, non-small cell lung cancer. One was the data I just showed about bevacizumab. Bevacizumab, Uh, when it was utilized in patients with squamous cell carcinoma, had an unacceptable rate of, uh, pulmonary hemorrhage, which unfortunately, in some cases was fatal. Um, and the other data set really was, uh, this study, which, uh, looked at cisplatin and Pemitrex in, which at the time was a fairly new chemotherapeutic versus cisplatin and, uh, gemcitabine. And what you can see here is that there were clear benefits with the pemitrexate, uh, arm doing, doing better in, in the adenocarcinoma. Whereas, um, really in the squamous, uh, it looked like the gemcitabine arm was Uh, a better arm. Then we saw what I would argue is real, uh, improvements in, uh, targeted therapy. But initially, we actually didn't know who the targets were. Um, this is a data set I was involved with years ago. And I just think graphically shows very nicely the outcome. You can see, um, On the left, you can see a patient who is, uh, you know, has extensive disease. You can see the results in the middle figure over here on the left. Um, actually, only a couple of weeks into therapy, um, followed by, by, by a couple of months, really, uh, significant improvement overall. Um, interestingly, this was with, uh, an EGFR inhibitor. And there was a time when there was really uh sort of uh quite considerable discussion about who are the patients who benefited from uh an EGFR inhibitor. There were some people who felt that it was really best assessed on clinical characteristics, some who were looking at EGFR, uh, gene copy number, like what is done with, uh, with the related gene HERR2. Um, uh, and then that was really answered by, by Tony Mock and colleagues. Um, this study enrolled exclusively in East Asia. Patients had to have smoked less than 100 cigarettes per day. And what you can see here is if you look at the progression-free survival, when comparing, uh jafitinib in green to chemotherapy in yellow, On the left, you see these very bizarre progression-free survival curves that cross, uh, sort of right in the middle. And when you look at the right, you see why those curves crossed. And, um, they had, uh, sort of correlative data on many of the patients. And you can see that, uh, in the patients who had an EGFR mutation, the gefitinib, uh, the EGFR inhibitor in green, performed much better than chemotherapy. However, in the patients who did not have an EGFR mutation, Uh, the jafitinibine green was very, a very poor, uh, agent for treatment. And that is sort of two separate populations is what contributed to the overall sort of strange appearing progression for your survival curves. Um, EGFR was sort of the first, but you can see there were many different, um, of these. I list this as sort of a historical data set. Um, this was the Lung Cancer Mutation Consortium, which really broke, uh, patients with, uh, different Uh, mutations and adenocarcinoma into different sort of pie pieces here. Um, and, and the, this pie, uh, that you see, which separates different populations have become more refined over time. Um, and there even have been additional mutations that have been discovered. But these looking for driver mutations in many respects has revolutionized the management of non-small cell lung cancer. Um, well, the targeted therapy, uh, revolution was sort of, uh, ongoing. Another revolution in terms of selecting patients was coming in, uh, immunotherapy. Immunotherapy, um, is in many respects, a very different approach when compared to, um, sort of what we typically see for these targetable mutations, where we will have a tyrosy kinase inhibitor that directly blocks signaling. Um, but in this case, in many respects, the, the, the biomarkers still end up, uh, driving things. Here, you can see the original design of the keynote 001 study, which helped define the PDL1 biomarker for pembrolizumab. You can see as part of that, patients really were divided into three separate groupings. Those with PDL1 expression in less than 1% of their cells, those with expression in 1 to 49% of their cells, and those with expression in at least half of their cells. Um, obviously, expression here is denoted in brown. The cutoff as part of that study was 50%. But what you can see is it's sort of a stepwise curve. Here, you see, um, in purple, the prevalence of PDL1 expression in all screened patients. Um, and then in blue, um, the response rate amongst those patients. And as you can see, um, by, by the, the blue here, um, the higher the patient's PDL one expression, the greater the likelihood that the patient would have a benefit from, uh, PD one inhibition. That was seen also with respect, uh, not only to response rate, but also progression-free survival shown here with the greater than 50% patients doing significantly better. And, uh, this also played out with respect to overall survival with those with high expression doing particularly well. At the time when, uh, when this was ongoing, people wouldn't Uh, weren't that excited about showing this data cause there was a lot of, uh, controversy about the PDL1 biomarker. But here you can see it compared to, uh, crizotinib, uh, in both, uh, on the left, ALK gene rearranged, non-small cell lung cancer, and on the right, ROS1 gene rearranged, uh, non-small cell lung cancer. And as you can see, um, although pembrolizumab, uh, was not, the, the PDL1, uh, 50% or greater was not quite as predictive. Um, still, there are a lot of similarities between these curves. Um, and the time has sort of proven that this is a, uh, biomarker that has sort of, uh, continued to be part of our management. So it is not the only biomarker that we look at. Um, obviously, across histologies, people have looked at microsatellite instability. That tends not to be seen much very often with lung cancer. But one of the things that became very clear early on, um, this is data from the TCGA. And if you look, um, this is showing the number of mutations, uh, per tumor. And what you can see is melanoma on the right, followed by lung squamous cell, then lung adeno, um, then bladder. In many respects, it looks like you are going through, um, the, the approvals for PD one inhibitors, uh, or